Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. SK bioscience Co.,Ltd.
  6. Summary
    A302440   KR7302440003

SK BIOSCIENCE CO.,LTD.

(A302440)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
09/15/2021 09/16/2021 09/17/2021 09/23/2021 09/24/2021 Date
280000 280000 272500 259000 274500 Last
837558 683777 1610697 2125317 1952991 Volume
+1.27% 0.00% -2.68% -4.95% +5.98% Change
Estimated financial data (e)
Sales 2021 1 074 B 0,91 B 0,91 B
Net income 2021 422 B 0,36 B 0,36 B
Net cash position 2021 596 B 0,51 B 0,51 B
P/E ratio 2021 48,5x
Yield 2021 -
Sales 2022 3 725 B 3,16 B 3,16 B
Net income 2022 1 242 B 1,05 B 1,05 B
Net cash position 2022 1 552 B 1,32 B 1,32 B
P/E ratio 2022 16,9x
Yield 2022 -
Capitalization 20 999 B 17 777 M 17 807 M
EV / Sales 2021 19,0x
EV / Sales 2022 5,22x
Nbr of Employees -
Free-Float 26,5%
More Financials
Company
SK Bioscience Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biological products. The Company's main products include vaccines such as SKYCellflu and Rotatech. The Company also sells infusion solutions. In addition, the Company engages in technology export business. The Company sells its products in domestic and overseas markets. 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about SK BIOSCIENCE CO.,LTD.
09/20SK BIOSCIENCE CO.,LTD.(KOSE : A302440) added to S&P Global BMI Index
CI
09/20SK BIOSCIENCE CO.,LTD.(KOSE : A302440) added to FTSE All-World Index
CI
09/07Vaccine makers should supply shots for trials to help spur sector -CEPI
RE
08/31GlaxoSmithKline, SK Bioscience Begin Phase 3 Trial of Covid-19 Vaccine
DJ
08/31S. Korean COVID-19 vaccine in late-stage test against AstraZeneca shot
RE
08/31SK Bio, GSK Start Late-Stage COVID-19 Vaccine Trial
RE
08/31SK BIOSCIENCE : GSK, SK Bioscience start late-stage trials of COVID-19 vaccine
RE
08/09South Korea approves Phase III trial of SK Bioscience's COVID-19 vaccine
RE
08/05S.Korea pledges nearly $2 bln to become major COVID-19 vaccine producer
RE
06/21SK BIOSCIENCE : S.Korea's SK bioscience to invest $132 million to boost vaccine production
RE
06/11SK BIOSCIENCE CO.,LTD.(KOSE : A302440) added to KOSPI 200 Index
CI
05/24NOVAVAX : Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine A..
AQ
05/24Samsung BioLogics shares ease after jumping on vaccine deal
RE
05/22U.S. vaccine makers agree to produce more COVID-19 vaccines in South Korea
RE
05/21VIR BIOTECHNOLOGY : EMA issues positive scientific opinion on GSK and Vir Biotechnology's ..
AQ
More news
News in other languages on SK BIOSCIENCE CO.,LTD.
08/31GlaxoSmithKline y SK Bioscience inician ensayo de Fase 3 de vacuna Covid-19
08/31GSK y SK Bioscience evaluarán su vacuna contra la COVID-19 frente a la de AZ
08/31MÄRKTE ASIEN/Fester - Kospi von Samsung-Aktie angetrieben
08/31S. Le vaccin coréen COVID-19 en phase finale de test contre le vaccin d'AstraZeneca
06/03MÄRKTE ASIEN/Überwiegend aufwärts - China-Börsen mit Abgaben
More news
Chart SK BIOSCIENCE CO.,LTD.
Duration : Period :
SK bioscience Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SK BIOSCIENCE CO.,LTD.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 274 500,00 KRW
Average target price 326 666,67 KRW
Spread / Average Target 19,0%
EPS Revisions
Managers and Directors
Jae-Yong An Chief Executive Officer & Director
Hun Kim Chief Technology Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
SK BIOSCIENCE CO.,LTD.0.00%17 777
CSL LIMITED10.18%103 032
WUXI BIOLOGICS (CAYMAN) INC.14.59%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336